Published on September 9, 2009 at 4:55 AM
Ernest B. Remo, Chairman/CEO of American Diversified Holdings Corporation (Pink Sheets: ADHC), announced today that ADHC has entered into a broad strategic alliance with INVENT Pharmaceuticals, Inc. Under the terms of the agreement ADHC will provide advisory services to INVENT ranging from equity investment, capital formation, regulatory compliance, financial and business operational consulting. American Diversified is eligible under the terms of the agreement to become a major equity shareholder in INVENT Pharmaceuticals upon successful capital formation. As a strategic partner, ADHC will provide consulting services to INVENT to enhance operational efficiency, business and corporate development, and positioning the company for IPO, and/or M&A by a major pharmaceutical or a biotech company.
Dr. Dale Dhanoa has been appointed a founding member of the Medical and Scientific Advisory Board of ADHC and will join internationally renowned anti-aging and wellness physician Dr. George Weiss.
Ernest B. Remo, Chairman of ADHC, commented, “This alliance with INVENT Pharma will enhance and diversify our investment focus in the biotech industry. We have now broadened our interest from the embryonic stem cell arena to development of small molecule therapeutics. The INVENT alliance has now put ADHC on the map as a developer of innovative solutions and therapies in the biotech sector that can potentially help patients suffering from debilitating diseases.”
Dr. Dhanoa, President and CEO of INVENT Pharmaceuticals, added, “This strategic alliance with ADHC is an ideal partnership for our company. We feel that we are now in a much more visible position to present our story to Wall Street and the international financial community. We are fully committed to integrate the financial advice, increased market recognition, visibility to potential investors and drug development partners into our cooperate plan. We are primed for major milestone development of our core technologies and this partnership is a key component to this strategy.”
http://www.inventpharma.com